AgingResearch.NewsJoin free

Zenas BioPharma

CompanyUnited States

Zenas BioPharma develops one asset, in phase 3 (orelabrutinib in multiple sclerosis (ms) primary progressive). Mostly small molecule acting on inflammation and BTK; based in the United States.

1
Asset
Furthest
Phase 3
2
Trials
0
Signals

Pipeline

1

  • orelabrutinib

    CNS-penetrable Bruton's tyrosine kinase (BTK) inhibitor reducing B cell and microglia-mediated inflammation.

    Phase 3, Small molecule, Inflammation, BTK, multiple sclerosis (ms) primary progressive, secondary progressive multiple sclerosis

Full company profiles: pipeline, trials, funding and people.

See Pro

In the full profile

  • Evidence behind the mechanisms2
  • Trials2
  • Signals1
  • Similar companies6

Updated 9 Oct 2026 · 6 sources

Intelligence